Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare have created innovative drug delivery technologies to address unmet clinical needs with superior tolerability and efficacy. Our Hyaluronan Drug Delivery (HDD) technology platform offers partners ready-made targeted and sustained release solutions which are adaptable to multiple drug, peptide or nucleic acid based systems.

Hyaluronan Drug Delivery (HDD) technology is based on the biological polymer sodium hyaluronate and leverages the molecules excellent biocompatibility, adaptability and cellular targeting functions as a ligand for receptors such as CD44.

We offer multiple HDD technologies including HA conjugated drugs (HACD), sustained release depot technology (DEPOT), trans-mucosal drug delivery technologies (TMDD) and HA nanoparticles (HANP) with each technology already proven in either clinical or pre-clinical models.

The HACD platform aids drug solubility and tumour targeting and is proven in human clinical treatment of metastatic colorectal cancer. HACD technology is fully transferable to other solid tumour types. HACD is also combinable with our sustained release sub-cutaneous DEPOT delivery technology.

Similarly the TMDD platform is also proven in human clinical treatment of ulcerative colitis as a novel way of sustaining release of small molecule drugs through its unique mucoadhesive stratgy and our multi-layer tablet coating (MLCP) delivery technologies.

Holy Stone have over twenty years experience of HDD technology and our in house development and GMP manufacturing teams have proven track record of adapting our technologies to suit multiple drug, peptide and nucleic acid based systems. Our in house regulatory expertise works hand in hand to successfully guide candidate products through pre-clinical development, clinical development and beyond.

Our HDD platforms are ready to deliver your therapeutic agent. Talk to us at Booth 18H6 to see how we can deliver your agent.